This month
The amylin half of Novo Nordisk's new combo drug just made headlines — but coverage gave it all to the GLP-1
At the American Diabetes Association's Scientific Sessions in New Orleans this month, Novo Nordisk presented first-look Phase 3 data from the REIMAGINE trials — the clinical program testing CagriSema in adults with type 2 diabetes. The results, published in [The Lancet Diabetes & Endocrinology](https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00126-9/abstract), showed that CagriSema outperformed either of its component agents individually for glycemic management and weight loss. Coverage from New Orleans ran wide. The word that anchored almost every headline was semaglutide — which is the GLP-1 receptor agonist half of the fixed-dose combination drug and the name with the existing brand recognition. The other word — cagrilintide — showed up in about 60% fewer places. That is not a trivial omission. [Novo Nordisk filed the NDA for CagriSema with the FDA on December 18, 2025](https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html), calling it the first injectable combination of a GLP-1 receptor agonist and an amylin analog for weight management. If approved, the drug's whole mechanism story changes — and the part that changes it is not the semaglutide. It is the other one.
The other half
What an amylin analog is and why it engages a separate satiety pathway from GLP-1
GLP-1 receptor agonists like semaglutide work primarily through a central appetite-suppression mechanism and delayed gastric emptying — signaling through the GLP-1 receptor to reduce food intake and slow the arrival of nutrients. Amylin is a different endogenous peptide hormone entirely. It is secreted alongside insulin from beta cells in the pancreas in response to meals and signals through the area postrema — a region in the brainstem involved in nausea, satiety, and food-intake regulation. Its biological roles include suppressing post-meal glucagon release, slowing gastric emptying through a mechanism that partially overlaps with but is distinct from GLP-1, and modulating neural pathways related to satiety. Pramlintide (Symlin), the FDA-approved amylin analog that has existed since 2005, established this biology in a clinical setting, though its three-times-daily dosing requirement limited uptake. Cagrilintide is an engineered long-acting version: modified to enable once-weekly administration and to align with the GLP-1 drug dosing schedule that patients already know. The combination logic is mechanistically coherent — two separate satiety pathways running in parallel through one injection. [The PubMed literature on cagrilintide](https://pubmed.ncbi.nlm.nih.gov/?term=cagrilintide) documents how this mechanism translates into clinical investigation.
The 22% conversation
The weight-loss number that's reshaping the GLP-1 conversation came from a combination drug
The statistic that landed in June 2026 wasn't 15%. It was 22.7% — the mean weight reduction reported for CagriSema in the REDEFINE 1 Phase 3 trial, [published in the NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2502082), across 3,417 participants without type 2 diabetes over 68 weeks. Semaglutide alone, from its own pivotal STEP 1 trial, showed approximately 14.9% mean body weight reduction. The gap is significant enough that patient forums and obesity medicine communities are already running the comparison. Telehealth discussion in June 2026 has shifted toward the question of whether existing semaglutide patients should wait for a combination drug rather than continuing on a single agent. On the other side of that conversation, with gray-market peptide interest running high after the compounding-semaglutide access window closed, a different question is circulating: since cagrilintide is what makes the combination work, can someone just get cagrilintide separately? The answer to that question matters, and it's different from the question about the approved combination. [The FDA's concerns about unapproved GLP-1 and related drugs](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) apply directly here.
What the data says
The REDEFINE and REIMAGINE programs give cagrilintide more clinical data than almost any research peptide has
[The clinical record for cagrilintide on ClinicalTrials.gov](https://clinicaltrials.gov/search?term=cagrilintide) includes the REDEFINE program — multiple Phase 3 trials for weight management including REDEFINE 1 and REDEFINE 2 (enrolling both participants with and without type 2 diabetes) — and the REIMAGINE program covering glycemic management in T2D. This is not a preclinical peptide with a mechanism story and no human outcome data. Cagrilintide has been rigorously studied in combination with semaglutide at the Phase 3 level, with outcomes data published in major peer-reviewed journals. The relevant nuance: almost all of the large human evidence for cagrilintide comes from the combination context — the REDEFINE and REIMAGINE programs are studying CagriSema, not cagrilintide as a standalone agent. What the Phase 3 data confirms is that when cagrilintide is added to semaglutide under controlled trial conditions, at specific doses, in studied populations, the additive effect on weight outcomes is substantial and measurable. It does not confirm what cagrilintide alone does at different doses, what it does in healthy adults not enrolled in obesity trials, or what any compounded version outside the trial formulation would produce.
Early human — PeptideFactCheck stance
Real Phase 3 data with an approved-drug NDA pending — and a gap between the trial and outside the trial
Cagrilintide holds the Early human evidence tier on PeptideFactCheck: interesting enough to watch, too early for broad certainty. That tier reflects something specific here. The early human data for cagrilintide is not early in the way most research peptides are early — there are Phase 3 programs, peer-reviewed publications, and an NDA pending FDA review. Early in this context means early to approval: the combination drug has not been approved, the approval process is underway, and the study population and dosing are specific to the clinical program. The gap that matters most in June 2026 is between CagriSema the NDA-pending combination drug and cagrilintide the peptide circulating in optimization forums as the "next weight-loss mechanism." The first is going through the approval process with clinical-program data behind it. The second is a different situation — one where the compound is being used outside the trial context, outside the approved combination, and under conditions the clinical data does not describe. The amylin biology is real. The REIMAGINE data is published. The distance between both of those things and an approved, compounded, or optimized single-agent use is the distance this tier is meant to flag.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.